Please use this identifier to cite or link to this item: http://hdl.handle.net/11718/26008
Title: Generic competition and the incentives for early-stage pharmaceutical innovation
Authors: Branstetter, Lee
Chatterjee, Chirantan
Higgins, Matthew J.
Keywords: Pharmaceutical innovation;Generic entry;Nature of innovation;Innovation policy
Issue Date: 1-Dec-2022
Publisher: Elsevier
Citation: Branstetter, L., Chatterjee, C., & Higgins, M. J. (2022). Generic competition and the incentives for early-stage pharmaceutical innovation. Research Policy, 51(10), 104595. https://doi.org/10.1016/J.RESPOL.2022.104595
Abstract: What impact has rising generic competition had on the nature and direction of pharmaceutical innovation? We find broad-based, strong evidence that pharmaceutical companies have diverted their new drug development efforts away from therapeutic markets already well-served by generic drugs. We also find that increasing generic competition induces firms to shift their R&D activity toward more biologic-based products and away from chemical-based products. We conclude by discussing potential implications of our results for long-run innovation policy.
URI: http://hdl.handle.net/11718/26008
ISSN: 0048-7333
Appears in Collections:Journal Articles

Files in This Item:
File Description SizeFormat 
Generic_competition_and_the_incentives_for_early-stage_pharmaceutical_innovation.pdf
  Restricted Access
Generic_competition_and_the_incentives_for_early-stage_pharmaceutical_innovation729.04 kBAdobe PDFView/Open Request a copy


Items in IIMA Institutional Repository are protected by copyright, with all rights reserved, unless otherwise indicated.